Fresenius : with solid H1 results – Accelerated earnings growth expected in H2 – New FY/20 guidance including COVID-19 effects

• Contact

  Matthias Link

  Senior Vice President Corporate Communications
  T: [phone]
  [e-mail]

• Documents

• Fresenius Medical Care with very strong earnings growth and exceptional cash flow development in Q2
• Fresenius Kabi impacted by fewer elective procedures and easing extra demand for COVID 19 related products in Europe and the U.S.; only gradual recovery in China
• Fresenius Helios seeing gradual return of elective procedures; Helios Germany supported by law to ease financial burden on hospitals; COVID-19 related reimbursement at Helios Spain with remaining uncertainties
• Fresenius Vamed heavily impacted by COVID-19 related project delays and lack of post-acute care treatments

Stephan Sturm, CEO of Fresenius, said:'Particularly during the COVID-19 pandemic, Fresenius continues to make many important contributions to the provision of high-quality, affordable healthcare. In this way, we are standing with our patients around the world - and fulfilling our social responsibility. Despite the extra effort and restrictions - in particular in our hospital business - we achieved a very solid second quarter. Special credit for this should go to the tremendous dedication of our more than 300,000 employees. Fresenius stands on a broad, strong foundation, whose resilience is being proved more than ever right now. Even with all the current uncertainties, we expect increasingly dynamic earnings development in the coming quarters. I therefore remain confident that 2020 will be another successful year for Fresenius.'

(...)

The complete news will be available here shortly. Until then please use the attached PDF.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.